Nasdaq

Next-Generation CyTOF XT Redefines Cytometry with Advances in Automation, Throughput, Time to Results and Total Cost of Ownership

SOUTH SAN FRANCISCO, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health ...
Business Wire

Fluidigm Introduces Advanced Mass Cytometry System Along With Sample Barcoding for Markedly Improved Discovery Workflows

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Fluidigm Corporation (NASDAQ:FLDM) today introduced Helios TM, a CyTOF ® platform that enables system-level biology at single-cell resolution, on an ...
GEN

DVS Sciences Raises $14.6M for Multiparameter Single-Cell Mass Cytometry Platform

Firm claims CyTOF MAXPAR System will enable analysis of up to 100 labels in a single sample. University of Toronto spin-out DVS Sciences raised $14.6 million in a Series A round of financing with ...
technologynetworks

CyTOF XT: The Next Evolution of Cytometry

Mass cytometry, with detection by TOF, has been a transformative single-cell technology in immunology, immunophenotyping, oncology and infectious disease studies for a decade. It is in use in over 150 ...
Nasdaq

Fluidigm Revolutionizes Next-Generation Sequencing RNA Library Preparation with Microfluidic Automation

SOUTH SAN FRANCISCO, Calif., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive ...